RNA Nanotherapeutics with Fibrosis Overexpression and Retention for MASH Treatment
Tuesday, July 15, 2025
3:27 PM – 3:38 PM EDT
Introduction: Metabolic dysfunction-associated steatohepatitis (MASH) is a chronic liver inflammatory disease with significant morbidity and mortality worldwide. Protein-based therapies hold promise for MASH treatment. However, the drug level in fibrotic lesions is often difficult to meet the therapeutic threshold due to non-specific distribution and rapid clearance. Therefore, targeted delivery and retention of therapeutic proteins is urgently needed for effective MASH treatment.
Learning Objectives:
At the completion of this activity, participants will know
Explain the underlying mechanism in the RNA delivery efficiency of retinoic acids based LNP.
Understand the necessity to optimize the sequence of the CBD-based therapeutic fusion proteins.
Clarify the advantages of the strategy in extending duration and minimizing systemic exposure.
